 BOSTON, Nov. 07, 2022 GLOBE NEWSWIRE -- Praxis Precision Medicines, Inc. NASDAQ: PRAX, a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system CNS disorders characterized by neuronal excitation-inhibition imbalance, today announced that management will participate in the following upcoming investor conferences: 